1. Ahmad A, Patel I, Parimilakrishnan S, Mohanta GP, Chung H, Chang J. The role of pharmacoeconomics in current Indian healthcare system. J Res Pharm Practice. 2013;2(1):3.
2. Annemans L, Minjoulat-Rey MC, De Knock M, Vranckx K, Czarka M, Gabriël S, Haentjens P. Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery in Belgium. Acta Clinica Belgica. 2014.
3. Bamber L, Muston D, McLeod E, Guillermin A, Lowin J, Patel R. Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist. Thrombosis J. 2015;13(1):1.
4. Becker RV III, Dembek C. Effects of cohort selection on the results of cost-effectiveness analysis of disease-modifying drugs for relapsing-remitting multiple sclerosis. J Manag Care Pharm. 2011;17(5):377–81.
5. Bjorvatn A, Kristiansen F. Fondaparinux sodium compared with enoxaparin sodium. Am J Cardiovasc Drugs. 2005;5(2):121–30.